RxDoctor Payments Data

Jennifer Bramhall

Family · Richland, WANPI 1871042689

Payments from drug & device makers

$548in general payments, 2019–2025

Across 11 payments — averaging $49.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$286
  • Baxter Healthcare$48
  • Medtronic$40
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$32
  • Boston Scientific$31
  • Johnson & Johnson$29
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$548 in reported general payments places this provider in the 70th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$81,910
Medicare patients
735
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban565$617,503
XareltoRivaroxaban121$134,524
EntrestoSacubitril/Valsartan95$125,718
JardianceEmpagliflozin84$91,318
Repatha SureclickEvolocumab24$21,945
FarxigaDapagliflozin Propanediol14$15,616
Metoprolol Succinate791$13,493
Atorvastatin Calcium603$6,870
Praluent PenAlirocumab11$5,169
Dabigatran EtexilateDabigatran Etexilate Mesylate12$4,860
Isosorbide Mononitrate ErIsosorbide Mononitrate303$4,198
Dofetilide27$3,866
Losartan Potassium326$3,817
Flecainide Acetate85$3,571
Spironolactone409$3,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$29$134,524121 claims
Boehringer IngelheimJardiance$24$91,31884 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,706 family providers in Washington.

Other family in Richland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →